DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced an update on its European strategy to drive growth by establishing recovery as the goal for patients experiencing acute cardiac events. There are over 200,000 deaths annually in Germany, France, UK, Spain, Italy and Russia from acute myocardial infarction (AMI).(1) Abiomed’s portfolio of circulatory care products including Impella®, iPulseTM and AB5000® are approved in 27 European Union (EU) countries through CE-Mark approval, and Impella is now approved in over 40 countries outside the United States. Abiomed announced that it has continued to invest in its sales, clinical, marketing and field service teams in Europe, now totaling over 30 individuals, to promote recovery for acute heart failure patients and increase revenue growth. Revenue in Europe for the first two quarters of Abiomed’s fiscal year 2008 represented the highest six months revenue total for the region in Abiomed’s history. The Impella technology has been the subject of more than 40 publications.
